Abstract
Neuropathic pain is a common chronic pain condition that is caused by a lesion or disease of the somatosensory nervous system. The multitude of sensory negative and positive sensations and associated comorbidities have a major impact on quality of life of affected patients. Current treatment options often only lead to a partial pain relief or are even completely ineffective. In addition, many clinical trials for the development of new drugs have not met the primary endpoint. Therefore, there is still an unmet clinical need in neuropathic pain syndromes. One reason for this therapeutic dilemma could be the heterogeneity of neuropathic pain with a variety of pathophysiological pain mechanisms that are expressed differently in each patient regardless of the underlying disease etiology. Reclassification of neuropathic pain syndromes therefore focuses on the underlying mechanisms of pain development rather than the disease etiology. A priori stratification of patients based on these individual mechanisms could allow the identification of potential treatment responders and thus realize the concept of a mechanism-based treatment. As no biomarkers for pain mechanisms have been discovered yet, one has to rely on surrogate markers that are thought to be closely related to these mechanisms. In this chapter, we present promising predictive biomarkers, focusing in particular on sensory symptoms and signs assessed by patient-reported outcome measures and sensory testing, and discuss how these tools might be used in clinical trials in the future.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alsaloum M, Higerd GP, Effraim PR, Waxman SG (2020) Status of peripheral sodium channel blockers for non-addictive pain treatment. Nat Rev Neurol 16:689–705. https://doi.org/10.1038/s41582-020-00415-2
Arendt-Nielsen L, Larsen JB, Rasmussen S et al (2020) A novel clinical applicable bed-side tool for assessing conditioning pain modulation: proof-of-concept. Scand J Pain. https://doi.org/10.1515/sjpain-2020-0033
Attal N, Gaudé V, Brasseur L et al (2000) Intravenous lidocaine in central pain: a double-blind, placebo-controlled, psychophysical study. Neurology 54:564–574. https://doi.org/10.1212/wnl.54.3.564
Attal N, Rouaud J, Brasseur L et al (2004) Systemic lidocaine in pain due to peripheral nerve injury and predictors of response. Neurology 62:218–225
Attal N, Bouhassira D, Baron R et al (2011) Assessing symptom profiles in neuropathic pain clinical trials: can it improve outcome? Eur J Pain 15:441–443. https://doi.org/10.1016/j.ejpain.2011.03.005
Attal N, de Andrade DC, Adam F et al (2016) Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 15:555–565. https://doi.org/10.1016/S1474-4422(16)00017-X
Baron R, Tölle TR, Gockel U et al (2009) A cross-sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: differences in demographic data and sensory symptoms. Pain 146:34–40. https://doi.org/10.1016/j.pain.2009.06.001
Baron R, Binder A, Wasner G (2010) Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 9:807–819. https://doi.org/10.1016/S1474-4422(10)70143-5
Baron R, Maier C, Attal N et al (2017) Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles. Pain 158:261–272. https://doi.org/10.1097/j.pain.0000000000000753
Baron R, Dickenson AH, Calvo M et al (2023) Maximizing treatment efficacy through patient stratification in neuropathic pain trials. Nat Rev Neurol 19:53–64. https://doi.org/10.1038/s41582-022-00741-7
Bennett MI, Smith BH, Torrance N, Potter J (2005) The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research. J Pain 6:149–158. https://doi.org/10.1016/j.jpain.2004.11.007
Bouhassira D, Attal N, Fermanian J et al (2004) Development and validation of the neuropathic pain symptom inventory. Pain 108:248–257. https://doi.org/10.1016/j.pain.2003.12.024
Bouhassira D, Attal N, Alchaar H et al (2005) Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 114:29–36. https://doi.org/10.1016/j.pain.2004.12.010
Bouhassira D, Wilhelm S, Schacht A et al (2014) Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: data from the randomized, double-blind, COMBO-DN study. Pain 155:2171–2179. https://doi.org/10.1016/j.pain.2014.08.020
Bouhassira D, Banders S, Attal N et al (2020) Stratification of patients based on the neuropathic pain symptom inventory (NPSI): development and validation of a new algorithm. Pain. https://doi.org/10.1097/j.pain.0000000000002130
Brasch-Andersen C, Møller MU, Christiansen L et al (2011) A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTR2C). Eur J Clin Pharmacol 67:1131–1137. https://doi.org/10.1007/s00228-011-1056-x
Campbell CM, Buenaver LF, Raja SN et al (2015) Dynamic pain phenotypes are associated with spinal cord stimulation-induced reduction in pain: a repeated measures observational pilot study. Pain Med 16:1349–1360. https://doi.org/10.1111/pme.12732
Celikbilek A, Tanik N, Sabah S et al (2014) Elevated neurofilament light chain (NFL) mRNA levels in prediabetic peripheral neuropathy. Mol Biol Rep 41:4017–4022. https://doi.org/10.1007/s11033-014-3270-y
Chaudhry M, Alessandrini M, Rademan J et al (2017) Impact of CYP2D6 genotype on amitriptyline efficacy for the treatment of diabetic peripheral neuropathy: a pilot study. Pharmacogenomics 18:433–443. https://doi.org/10.2217/pgs-2016-0185
Choi K, Kwon O, Suh BC et al (2022) Subgrouping of peripheral neuropathic pain patients according to sensory symptom profile using the Korean version of the PainDETECT questionnaire. J Korean Med Sci 37:e8. https://doi.org/10.3346/jkms.2022.37.e8
de Greef BTA, Hoeijmakers JGJ, Geerts M et al (2019) Lacosamide in patients with Nav1.7 mutations-related small fibre neuropathy: a randomized controlled trial. Brain 142:263–275. https://doi.org/10.1093/brain/awy329
Demant DT, Lund K, Vollert J et al (2014) The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. Pain 155:2263–2273. https://doi.org/10.1016/j.pain.2014.08.014
Demant DT, Lund K, Finnerup NB et al (2015) Pain relief with lidocaine 5% patch in localized peripheral neuropathic pain in relation to pain phenotype: a randomised, double-blind, and placebo-controlled, phenotype panel study. Pain 156:2234–2244. https://doi.org/10.1097/j.pain.0000000000000266
Edwards RR, Dworkin RH, Turk DC et al (2016) Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations. Pain 157:1851–1871. https://doi.org/10.1097/j.pain.0000000000000602
European Medicines Agency (2016) EMA/CHMP/970057/2011: guideline on the clinical development of medicinal products intended for the treatment of pain. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-development-medicinal-products-intended-treatment-pain-first-version_en.pdf. Accessed 24 Feb 2021
Fields HL, Rowbotham M, Baron R (1998) Postherpetic neuralgia: irritable nociceptors and deafferentation. Neurobiol Dis 5:209–227. https://doi.org/10.1006/nbdi.1998.0204
Finnerup NB, Sindrup SH, Bach FW et al (2002) Lamotrigine in spinal cord injury pain: a randomized controlled trial. Pain 96:375–383
Finnerup NB, Biering-Sørensen F, Johannesen IL et al (2005) Intravenous lidocaine relieves spinal cord injury pain: a randomized controlled trial. Anesthesiology 102:1023–1030. https://doi.org/10.1097/00000542-200505000-00023
Finnerup NB, Attal N, Haroutounian S et al (2015) Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 14:162–173. https://doi.org/10.1016/S1474-4422(14)70251-0
Finnerup NB, Haroutounian S, Kamerman P et al (2016) Neuropathic pain: an updated grading system for research and clinical practice. Pain 157:1599–1606. https://doi.org/10.1097/j.pain.0000000000000492
Freeman R, Baron R, Bouhassira D et al (2014) Sensory profiles of patients with neuropathic pain based on the neuropathic pain symptoms and signs. Pain 155:367–376. https://doi.org/10.1016/j.pain.2013.10.023
Freynhagen R, Baron R, Gockel U, Tölle TR (2006) painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 22:1911–1920. https://doi.org/10.1185/030079906X132488
Freynhagen R, Tölle TR, Gockel U, Baron R (2016) The painDETECT project – far more than a screening tool on neuropathic pain. Curr Med Res Opin 32:1033–1057. https://doi.org/10.1185/03007995.2016.1157460
Galer BS, Jensen MP (1997) Development and preliminary validation of a pain measure specific to neuropathic pain: the neuropathic pain scale. Neurology 48:332–338. https://doi.org/10.1212/wnl.48.2.332
Gierthmühlen J, Binder A, Förster M, Baron R (2018) Do we measure what patients feel?: An analysis of correspondence between somatosensory modalities upon quantitative sensory testing and self-reported pain experience. Clin J Pain 34:610–617. https://doi.org/10.1097/AJP.0000000000000582
Hostrup SNF, O’Neill SFD, Larsen JB et al (2022) A simple, bed-side tool to assess evoked pressure pain intensity. Scand J Pain. https://doi.org/10.1515/sjpain-2022-0055
Izumi M, Hayashi Y, Saito R et al (2022) Detection of altered pain facilitatory and inhibitory mechanisms in patients with knee osteoarthritis by using a simple bedside tool kit (QuantiPain). Pain Rep 7:e998. https://doi.org/10.1097/PR9.0000000000000998
Jain SM, Balamurugan R, Tandon M et al (2022) Randomized, double-blind, placebo-controlled trial of ISC 17536, an oral inhibitor of transient receptor potential ankyrin 1, in patients with painful diabetic peripheral neuropathy: impact of preserved small nerve fiber function. Pain 163:e738–e747. https://doi.org/10.1097/j.pain.0000000000002470
Jamison RN, Edwards RR, Liu X et al (2013) Relationship of negative affect and outcome of an opioid therapy trial among low back pain patients. Pain Pract 13:173–181. https://doi.org/10.1111/j.1533-2500.2012.00575.x
Jensen MP, Gammaitoni AR, Olaleye DO et al (2006) The pain quality assessment scale: assessment of pain quality in carpal tunnel syndrome. J Pain 7:823–832. https://doi.org/10.1016/j.jpain.2006.04.003
Jensen TS, Baron R, Haanpää M et al (2011) A new definition of neuropathic pain. Pain 152:2204–2205. https://doi.org/10.1016/j.pain.2011.06.017
Keller T, Freynhagen R, Tölle TR et al (2016) A retrospective analysis of the long-term test-retest stability of pain descriptors of the painDETECT questionnaire. Curr Med Res Opin 32:343–349. https://doi.org/10.1185/03007995.2015.1125869
Kim S-H, Choi MK, Park NY et al (2020) Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy. Sci Rep 10:7995. https://doi.org/10.1038/s41598-020-64511-5
Koulouris AE, Edwards RR, Dorado K et al (2020) Reliability and validity of the Boston bedside quantitative sensory testing battery for neuropathic pain. Pain Med 21:2336–2347. https://doi.org/10.1093/pm/pnaa192
Krause SJ, Backonja M-M (2003) Development of a neuropathic pain questionnaire. Clin J Pain 19:306–314. https://doi.org/10.1097/00002508-200309000-00004
Lewis GN, Rice DA, McNair PJ (2012) Conditioned pain modulation in populations with chronic pain: a systematic review and meta-analysis. J Pain 13:936–944. https://doi.org/10.1016/j.jpain.2012.07.005
Mackey S, Greely HT, Martucci KT (2019) Neuroimaging-based pain biomarkers: definitions, clinical and research applications, and evaluation frameworks to achieve personalized pain medicine. Pain Rep 4:e762. https://doi.org/10.1097/PR9.0000000000000762
Magerl W, Krumova EK, Baron R et al (2010) Reference data for quantitative sensory testing (QST): refined stratification for age and a novel method for statistical comparison of group data. Pain 151:598–605. https://doi.org/10.1016/j.pain.2010.07.026
Mahn F, Hüllemann P, Gockel U et al (2011) Sensory symptom profiles and co-morbidities in painful radiculopathy. PloS One 6:e18018. https://doi.org/10.1371/journal.pone.0018018
Marchettini P, Wilhelm S, Petto H et al (2016) Are there different predictors of analgesic response between antidepressants and anticonvulsants in painful diabetic neuropathy? Eur J Pain 20:472–482. https://doi.org/10.1002/ejp.763
Merskey H, Bogduk N (1994) Part III: pain terms, a current list with definitions and notes on usage. In: Classification of chronic pain, second edition, IASP task force on taxonomy. IASP Press, Seattle, pp 209–214
Morgenstern J, Groener JB, Jende JME et al (2021) Neuron-specific biomarkers predict hypo- and hyperalgesia in individuals with diabetic peripheral neuropathy. Diabetologia 64:2843–2855. https://doi.org/10.1007/s00125-021-05557-6
Namer B, Schmidt D, Eberhardt E et al (2019) Pain relief in a neuropathy patient by lacosamide: proof of principle of clinical translation from patient-specific iPS cell-derived nociceptors. EBioMedicine 39:401–408. https://doi.org/10.1016/j.ebiom.2018.11.042
Ossendorf A (2019) Krankheitskostenanalyse bei Patienten mit chronischen neuropathischen Schmerzen. Gesundh ökon Qual manag 24:42–50. https://doi.org/10.1055/a-0600-3655
Otto JC, Forstenpointner J, Sachau J et al (2019) A novel algorithm to identify predictors of treatment response: tapentadol monotherapy or tapentadol/pregabalin combination therapy in chronic low back pain? Front Neurol 10:979. https://doi.org/10.3389/fneur.2019.00979
Packham TL, Cappelleri JC, Sadosky A et al (2017) Measurement properties of painDETECT: Rasch analysis of responses from community-dwelling adults with neuropathic pain. BMC Neurol 17:48. https://doi.org/10.1186/s12883-017-0825-2
Petersen KK, Graven-Nielsen T, Simonsen O et al (2016) Preoperative pain mechanisms assessed by cuff algometry are associated with chronic postoperative pain relief after total knee replacement. Pain 157:1400–1406. https://doi.org/10.1097/j.pain.0000000000000531
Petersen KK-S, Drewes AM, Olesen AE et al (2022) The effect of duloxetine on mechanistic pain profiles, cognitive factors and clinical pain in patients with painful knee osteoarthritis-A randomized, double-blind, placebo-controlled, crossover study. Eur J Pain 26:1650–1664. https://doi.org/10.1002/ejp.1988
Portenoy R (2006) Development and testing of a neuropathic pain screening questionnaire: ID pain. Curr Med Res Opin 22:1555–1565. https://doi.org/10.1185/030079906X115702
Ranoux D, Attal N, Morain F, Bouhassira D (2008) Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 64:274–283. https://doi.org/10.1002/ana.21427
Reimer M, Hüllemann P, Hukauf M et al (2017) Prediction of response to tapentadol in chronic low back pain. Eur J Pain 21:322–333. https://doi.org/10.1002/ejp.926
Reimer M, Forstenpointner J, Hartmann A et al (2020) Sensory bedside testing: a simple stratification approach for sensory phenotyping. Pain Rep 5:e820. https://doi.org/10.1097/PR9.0000000000000820
Rolke R, Baron R, Maier C et al (2006a) Quantitative sensory testing in the German research network on neuropathic pain (DFNS): standardized protocol and reference values. Pain 123:231–243. https://doi.org/10.1016/j.pain.2006.01.041
Rolke R, Magerl W, Campbell KA et al (2006b) Quantitative sensory testing: a comprehensive protocol for clinical trials. Eur J Pain 10:77–88. https://doi.org/10.1016/j.ejpain.2005.02.003
Sachau J, Appel C, Reimer M et al (2023) Test-retest reliability of a simple bedside-quantitative sensory testing battery for chronic neuropathic pain. Pain Rep 8:e1049. https://doi.org/10.1097/PR9.0000000000001049
Sandelius Å, Zetterberg H, Blennow K et al (2018) Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology 90:e518–e524. https://doi.org/10.1212/WNL.0000000000004932
Schukro RP, Oehmke MJ, Geroldinger A et al (2016) Efficacy of duloxetine in chronic low back pain with a neuropathic component: a randomized, double-blind, placebo-controlled crossover trial. Anesthesiology 124:150–158. https://doi.org/10.1097/ALN.0000000000000902
Serra J, Collado A, Solà R et al (2014) Hyperexcitable C nociceptors in fibromyalgia. Ann Neurol 75:196–208. https://doi.org/10.1002/ana.24065
Serra J, Duan WR, Locke C et al (2015) Effects of a T-type calcium channel blocker, ABT-639, on spontaneous activity in C-nociceptors in patients with painful diabetic neuropathy: a randomized controlled trial. Pain 156:2175–2183. https://doi.org/10.1097/j.pain.0000000000000249
Simpson DM, Schifitto G, Clifford DB et al (2010) Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. Neurology 74:413–420. https://doi.org/10.1212/WNL.0b013e3181ccc6ef
Smith EML, Pang H, Ye C et al (2017) Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial – CALGB/alliance 170601. Eur J Cancer Care (Engl) 26. https://doi.org/10.1111/ecc.12421
Tesfaye S, Wilhelm S, Lledo A et al (2013) Duloxetine and pregabalin: high-dose monotherapy or their combination? The “COMBO-DN study” – a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain 154:2616–2625. https://doi.org/10.1016/j.pain.2013.05.043
Tölle TR, Baron R, de Bock E et al (2019) painPREDICT: first interim data from the development of a new patient-reported pain questionnaire to predict treatment response using sensory symptom profiles. Curr Med Res Opin 35:1177–1185. https://doi.org/10.1080/03007995.2018.1562687
van Hecke O, Austin SK, Khan RA et al (2014) Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain 155:654–662. https://doi.org/10.1016/j.pain.2013.11.013
Vollert J, Mainka T, Baron R et al (2015) Quality assurance for quantitative sensory testing laboratories: development and validation of an automated evaluation tool for the analysis of declared healthy samples. Pain 156:2423–2430. https://doi.org/10.1097/j.pain.0000000000000300
Vollert J, Magerl W, Baron R et al (2018) Pathophysiological mechanisms of neuropathic pain: comparison of sensory phenotypes in patients and human surrogate pain models. Pain 159:1090–1102. https://doi.org/10.1097/j.pain.0000000000001190
Wanigasekera V, Mezue M, Andersson J et al (2016) Disambiguating pharmacodynamic efficacy from behavior with neuroimaging: implications for analgesic drug development. Anesthesiology 124:159–168. https://doi.org/10.1097/ALN.0000000000000924
Wanigasekera V, Wartolowska K, Huggins JP et al (2018) Disambiguating pharmacological mechanisms from placebo in neuropathic pain using functional neuroimaging. Br J Anaesth 120:299–307. https://doi.org/10.1016/j.bja.2017.11.064
Wasan AD, Michna E, Edwards RR et al (2015) Psychiatric comorbidity is associated prospectively with diminished opioid analgesia and increased opioid misuse in patients with chronic low back pain. Anesthesiology 123:861–872. https://doi.org/10.1097/ALN.0000000000000768
Wasan AD, Alter BJ, Edwards RR et al (2020) Test-retest and inter-examiner reliability of a novel bedside quantitative sensory testing battery in postherpetic neuralgia patients. J Pain 21:858–868. https://doi.org/10.1016/j.jpain.2019.11.013
Woolf CJ, Bennett GJ, Doherty M et al (1998) Towards a mechanism-based classification of pain? Pain 77:227–229. https://doi.org/10.1016/S0304-3959(98)00099-2
Yarnitsky D (2015) Role of endogenous pain modulation in chronic pain mechanisms and treatment. Pain 156(Suppl 1):S24–S31. https://doi.org/10.1097/01.j.pain.0000460343.46847.58
Yarnitsky D, Arendt-Nielsen L, Bouhassira D et al (2010) Recommendations on terminology and practice of psychophysical DNIC testing. Eur J Pain 14:339. https://doi.org/10.1016/j.ejpain.2010.02.004
Yarnitsky D, Granot M, Nahman-Averbuch H et al (2012) Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. Pain 153:1193–1198. https://doi.org/10.1016/j.pain.2012.02.021
Yarnitsky D, Bouhassira D, Drewes AM et al (2015) Recommendations on practice of conditioned pain modulation (CPM) testing. Eur J Pain 19:805–806. https://doi.org/10.1002/ejp.605
Yu W, Zhao G-Q, Cao R-J et al (2017) LncRNA NONRATT021972 was associated with neuropathic pain scoring in patients with type 2 diabetes. Behav Neurol 2017:2941297. https://doi.org/10.1155/2017/2941297
Zhu GC, Böttger K, Slater H et al (2019) Concurrent validity of a low-cost and time-efficient clinical sensory test battery to evaluate somatosensory dysfunction. Eur J Pain 23:1826–1838. https://doi.org/10.1002/ejp.1456
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Sachau, J., Baron, R. (2023). Precision Medicine in Neuropathic Pain. In: Cascorbi, I., Schwab, M. (eds) Precision Medicine. Handbook of Experimental Pharmacology, vol 280. Springer, Cham. https://doi.org/10.1007/164_2023_662
Download citation
DOI: https://doi.org/10.1007/164_2023_662
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-40046-9
Online ISBN: 978-3-031-40047-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)